المؤلفون: De León AM; Department of Neurology, Emory University, Atlanta, Georgia, USA., Aban I; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA., McPherson T; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA., Granit V; Department of Neurology, University of Miami, Miami, Florida, USA., Benatar M; Department of Neurology, University of Miami, Miami, Florida, USA., Cutter G; Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA., Lee I; Department of Neurology, Columbia University, New York, New York, USA.

المصدر: Muscle & nerve [Muscle Nerve] 2023 Jan; Vol. 67 (1), pp. 25-32. Date of Electronic Publication: 2022 Nov 14.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 7803146 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4598 (Electronic) Linking ISSN: 0148639X NLM ISO Abbreviation: Muscle Nerve Subsets: MEDLINE

مواضيع طبية MeSH: COVID-19*/epidemiology , COVID-19*/complications , Myasthenia Gravis*/diagnosis, Humans ; Pandemics ; COVID-19 Testing ; Registries

مستخلص: Introduction/aims: Factors associated with coronavirus disease 2019 (COVID-19) infection among the myasthenia gravis (MG) population are incompletely understood. This study aimed to characterize the behavior of MG patients during the pandemic and to examine risk factors associated with COVID-19 infection.
Methods: A "COVID-19 Survey" was sent to MG Patient Registry participants in the summer of 2020 (CSS20) and winter of 2021 (CWS21). Survey results were summarized descriptively. Demographics, disease characteristics, medication use, and survey results were compared between those reporting COVID-19 diagnosis (COVID), COVID-19 like symptoms without diagnosis (COVID-Like), and asymptomatic participants.
Results: A total of 454 and 665 participants completed the CSS20 and CWS21 surveys respectively; 326 participants completed both. Most continued follow-up visits and MG treatments. The frequency of COVID-like symptoms was similar between CSS20 and CWS21, while COVID-19 exposure (6% vs. 27%), COVID-19 testing among symptomatic individuals (35% vs. 78%), and COVID-19 diagnosis (0.2% vs. 6%) were higher in the CWS21. Cough, fever, fatigue, myalgia, anosmia/ageusia, and hospital and intensive care unit (ICU) admissions were more frequent in the COVID compared to the COVID-Like group. COVID-19 exposure (odds ratio [OR] 7.88), number of people in the household (OR 1.31), and report of MG exacerbation before the pandemic (OR 2.6) were independently associated with COVID-19 infection.
Discussion: COVID-19 affected MG patients increasingly through the early pandemic. While face-to-face contact with a COVID-19 infected individual was an obvious risk factor, MG patients who had more people in the household and unstable disease were at elevated risk for COVID-19 infection.
(© 2022 Wiley Periodicals LLC.)